|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.000 USD | -5.06% |
|
-.--% | -12.54% |
| 06-26 | HLS Therapeutics Inc. - Shareholder/Analyst Call | |
| 06-23 | HLS Therapeutics to Begin its Normal Course Issuer Bid | MT |
Company Valuation: HLS Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 384.6 | 235.2 | 95.92 | 86.84 | 109.9 | 94.6 | - | - |
| Change | - | -38.85% | -59.22% | -9.47% | 26.6% | -13.95% | - | - |
| Enterprise Value (EV) | 384.6 | 235.2 | 95.92 | 86.84 | 109.9 | 94.6 | 94.6 | 94.6 |
| Change | - | -38.85% | -59.22% | -9.47% | 26.6% | -13.95% | 0% | 0% |
| P/E | -28.9x | -9.95x | -3.52x | -4.41x | -9.01x | -15.1x | -101x | 43.2x |
| PBR | - | 1.88x | - | 1.22x | - | 1.64x | 1.59x | - |
| PEG | - | -0.1x | -0.2x | 0.2x | 0.2x | 0.3x | 1.2x | -0x |
| Capitalization / Revenue | 6.41x | 3.83x | 1.52x | 1.53x | 1.98x | 1.63x | 1.47x | 1.23x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.63x | 1.47x | 1.23x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 4.89x | 4.03x | 2.9x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -22.5x | 63.1x | 13.5x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 9.01x | - | - |
| FCF Yield | 3.27% | 7.18% | 16.4% | 9.2% | 15.4% | 11.1% | - | - |
| Dividend per Share 2 | - | - | 0.7398 | - | - | - | - | - |
| Rate of return | - | - | 24.7% | - | - | - | - | - |
| EPS 2 | -0.41 | -0.73 | -0.85 | -0.62 | -0.39 | -0.2 | -0.03 | 0.07 |
| Distribution rate | - | - | -87% | - | - | - | - | - |
| Net sales 1 | 60.01 | 61.47 | 63.07 | 56.62 | 55.5 | 58.03 | 64.31 | 77.2 |
| EBITDA 1 | 26.33 | 23.83 | 21.05 | 16.65 | 19.62 | 19.34 | 23.45 | 32.65 |
| EBIT 1 | -6.284 | -13.5 | -10.35 | -7.686 | -4.106 | -4.2 | 1.5 | 7 |
| Net income 1 | -13.12 | -23.6 | -27.53 | -19.66 | -12.43 | -6.264 | -1.05 | 2.6 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 11.853 | 7.263 | 2.991 | 2.731 | 3.515 | 3.025 | 3.025 | 3.025 |
| Nbr of stocks (in thousands) | 32,451 | 32,384 | 32,071 | 31,793 | 31,274 | 31,275 | - | - |
| Announcement Date | 3/17/22 | 3/16/23 | 3/14/24 | 3/13/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 19.36x | 0.23x | 13.4x | 0.41% | 95.85B | ||
| 30.54x | 0.24x | 15.26x | 0.87% | 55.54B | ||
| 43.89x | 3.1x | 28.77x | 1.41% | 22.26B | ||
| 11.21x | 0.2x | 4.78x | 2.68% | 8.02B | ||
| 12.89x | 0.99x | 7.97x | 2.62% | 7.46B | ||
| 6.07x | 0.1x | 2.72x | 4.87% | 6.84B | ||
| 9.58x | 1.78x | 5.69x | 3.44% | 6.37B | ||
| 24.54x | 1.18x | 14.55x | 2.94% | 5.31B | ||
| 10.72x | 0.12x | 4.44x | 4.17% | 3.67B | ||
| Average | 18.76x | 0.88x | 10.84x | 2.6% | 23.48B | |
| Weighted average by Cap. | 23.60x | 0.63x | 14.29x | 1.16% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HLS Stock
- HLTRF Stock
- Valuation HLS Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
















